|
|||||
|
|
2,3-Diaminopyridine as a platform for designing structurally unique nonpeptide bradykinin B1 receptor antagonists |
|
| Authors: | Feng Dong-Mei Wai Jenny M Kuduk Scott D Ng Christina Murphy Kathy L Ransom Richard W Reiss Duane Chang Raymond S L Harrell Charles M MacNeil Tanya Tang Cuyue Prueksaritanont Thomayant Freidinger Roger M Pettibone Douglas J Bock Mark G |
| Institution: | Department of Medicinal Chemistry, Merck Research Laboratories, West Point, PA 19486, USA. dongmei_feng@merck.com |
| Abstract: | A novel class of 2,3-diaminopyridine bradykinin B1 receptor antagonists is disclosed. Structure-activity relationship studies (SARs) that led to compounds with significantly improved potency and pharmacokinetic properties relative to the lead compound are described. |
| Keywords: | |
| 本文献已被 ScienceDirect PubMed 等数据库收录！ | |